文献速递临床试验与 GCP

内镜治疗(内镜下球囊扩张/自膨式金属支架)与手术切除治疗克罗恩病新发狭窄的比较(ENDOCIR研究):一项开放标签、多中心、随机试验

Endoscopic treatment (endoscopic balloon dilation/self-expandable metal stent) vs surgical resection for the treatment of de novo stenosis in Crohn's disease (ENDOCIR study): an open-label, multicentre, randomized trial.
PubMed 文献 · Trials · 2023-06-27

ENDOCIR试验为探索性概念验证、多中心、开放标签、随机试验,拟在西班牙15家医院招募40例克罗恩病新发狭窄患者,随机分配至内镜治疗(球囊扩张/自膨式金属支架)组或手术切除组,主要终点为1年随访时生活质量改善(IBDQ-32评分增加30分的患者百分比),并评估临床复发率、并发症和费用。

要点

  • 克罗恩病新发狭窄长度小于10厘米者,内镜治疗与手术切除的优劣尚无科学证据。
  • 内镜治疗先采用内镜下球囊扩张,治疗失败时放置自膨式金属支架。
  • 主要终点为1年随访时IBDQ-32评分增加30分的患者百分比。

核心结论

  • ENDOCIR试验旨在确定内镜治疗与手术切除在克罗恩病新发狭窄治疗中何者更具治疗优势。

研究设计与样本

  • 探索性概念验证、多中心、开放标签、随机试验,比较内镜治疗(球囊扩张/自膨式金属支架)与手术切除治疗克罗恩病新发狭窄。
  • 计划招募40例克罗恩病新发狭窄患者,来自西班牙15家医院,随机分配至内镜治疗组或手术切除组。
  • 内镜治疗先采用内镜下球囊扩张,治疗失败时放置自膨式金属支架。
  • 预计招募期2年,随访1年评估生活质量、费用、并发症和临床复发,研究结束后再随访3年以重新评估长期变量。

关键数值与推荐

  • 主要目标为评估1年随访时患者生活质量,即32项炎症性肠病问卷(IBDQ-32)评分增加30分的患者百分比。
  • 次要目标为评估1年随访时两种治疗的临床复发率、并发症和费用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stenosis is one of the most common complications in patients with Crohn's disease (CD). Endoscopic balloon dilation (EBD) is the treatment of choice for a short stenosis adjacent to the anastomosis from previous surgery. Self-expandable metal stents (SEMS) may be a suitable treatment option for longer stenoses. To date, however, there is no scientific evidence as to whether endoscopic (EBD/SEMS) or surgical treatment is the best approach for de novo or primary stenoses that are less than 10 cm in length. METHODS/DESIGN: Exploratory study as "proof-of-concept", multicentre, open-label, randomized trial of the treatment of de novo stenosis in the CD; endoscopic treatment (EBD/SEMS) vs surgical resection (SR). The type of endoscopic treatment will initially be with EDB; if a therapeutic failure occurs, then a SEMS will be placed. We estimate 2 years of recruitment and 1 year of follow-up for the assessment of quality of life, costs, complications, and clinical recurrence. After the end of the study, patients will be followed up for 3 years to re-evaluate the variables over the long term. Forty patients with de novo stenosis in CD will be recruited from 15 hospitals in Spain and will be randomly assigned to the endoscopic or surgical treatment groups. The primary aim will be the evaluation of the patient quality of life at 1 year follow-up (% of patients with an increase of 30 points in the 32-item Inflammatory Bowel Disease Questionnaire (IBDQ-32). The secondary aim will be evaluation of the clinical recurrence rate, complications, and costs of both treatments at 1-year follow-up. DISCUSSION: The ENDOCIR trial has been designed to determine whether an endoscopic or surgical approach is therapeutically superior in the treatment of de novo stenosis in CD. TRIAL REGISTRATION: ClinicalTrials.gov NCT04330846. Registered on 1 April 1 2020. https://clinicaltrials.gov/ct2/home.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Loras C, Ruiz-Ramirez P, Romero J, et al. Endoscopic treatment (endoscopic balloon dilation/self-expandable metal stent) vs surgical resection for the treatment of de novo stenosis in Crohn's disease (ENDOCIR study): an open-label, multicentre, randomized trial. Trials. 2023. PMID: 37365665. doi:10.1186/s13063-023-07447-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。